23andme joins health tech’s Spacmania
But more traditional device makers seem uninterested in this means of stock market listing.
Medtech deal-making stands firm in difficult times
It takes more than a pandemic to stop medical device companies merging.
Astrazeneca shows megamergers were still possible in 2020
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Yumanity finds a shell in Proteostasis
Yumanity Therapeutics wants to be at the forefront of a neurodegenerative disease revolution, but is taking an unglamorous route to get there.
Philips spends big in-house while Becton favours buying
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Biopharma takeovers show quantity, if not quality
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
